Biotech News
Jazz Pharmaceuticals to Acquire Chimerix for $935M in Rare Oncology Expansion
Jazz Pharmaceuticals plc has entered into a definitive agreement to acquire Chimerix for approximately $935 million in cash. Under the terms, Jazz will pay $8.55 per share, representing a 72% premium on Chimerix’s closing price on March 4, 2025. The acquisition
6 March 2025